Targeting the urokinase plasminogen activation pathway reduces PDAC cancer progression.

被引：0
|
作者：
Chowdhury, Nayela N. [1 ]
Yang, Yi [2 ]
Shen, Yingnan [3 ]
Davey, Keely G. [2 ]
Han, Bumsoo [3 ]
Wolberg, Alisa [2 ]
Flick, Matthew J. [2 ]
Fishel, Melissa L. [1 ]
机构：
[1] Indiana Univ, Sch Med, Indianapolis, IN 46208 USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Purdue Univ, W Lafayette, IN 47907 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2002
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Silencing urokinase-type plasminogen activator in prostate cancer cells reduces their intraosseouis proliferation and bone degradation
    Dong, Z.
    Bonfil, R. D.
    Yamamoto, H. A.
    Chinni, S. R.
    Saliganan, A.
    Meng, H.
    Nabha, S. M.
    Sabbota, A.
    Wiesner, C.
    Cher, M. L.
    CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 37 - 38
  • [42] RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo
    Zhou, Han
    Tang, Yaling
    Liang, Xinhua
    Yang, Xiaoqin
    Yang, Jing
    Zhu, Guiquan
    Zheng, Min
    Zhang, Chunxu
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (02) : 453 - 462
  • [43] Polymorphisms in the Genes of the Urokinase Plasminogen Activation System in Relation to Non-Small Cell Lung Cancer
    Lee, Y. L.
    Chen, W.
    Chen, S. C.
    Cheng, W. E.
    Shih, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [44] Antiproteolytic therapy targeting urokinase-plasminogen activator for the treatment of breast cancer - a phase I study.
    Goldstein, LJ
    Cohen, RB
    Swaby, R
    Gallo, JM
    Bartz, R
    Muehlenweg, B
    Bevan, P
    Wilhelm, OG
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9060S - 9061S
  • [45] Elevated plasma levels of urokinase plasminogen activator and its receptor are strongly associated with prostate cancer presence and progression
    Sadeghi, F
    Shariat, S
    Kattan, MW
    Andrews, B
    Wheeler, TM
    Slawin, KM
    JOURNAL OF UROLOGY, 2003, 169 (04): : 161 - 161
  • [46] Targeting of urokinase-type plasminogen activator receptor in oral cancer cells inhibits invasion and metastasis in vivo
    Nozaki, Shinichi
    Endo, Yoshio
    Nakahara, Hirokazu
    Yoshizawa, Kunio
    Hashiba, Yukari
    Kawashiri, Shuichi
    Tanaka, Akira
    Nakagawa, Kiyomasa
    Yamamoto, Etsuhide
    CANCER RESEARCH, 2006, 66 (08)
  • [47] Targeting urokinase plasminogen activator: evaluation of activity-based imaging probes in an orthotopic breast cancer model
    Ides, Johan
    Vangestel, Christel
    Messagle, Jonas
    Verzele, Dieter
    Thomae, David
    Thys, Sofie
    Wouters, An
    Bogers, John-Paul
    Stroobants, Sigrid
    Joossens, Jurgen
    Van der Veken, Pieter
    Peeters, Marc
    Lardon, Filip
    Staelens, Steven
    Augustyns, Koen
    CANCER RESEARCH, 2013, 73 (08)
  • [48] Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer
    Shahdeo, Deepshikha
    Chandra, Akshay B.
    Gandhi, Sonu
    ANALYTICAL CHEMISTRY, 2021, 93 (34) : 11868 - 11877
  • [49] Expression of fibroblast growth factor receptor 1 isoforms and activation of different pathways in prostate cancer progression.
    Labanca, Estefania
    Yang, Jun
    Shepherd, Peter
    Roberts, Justin
    Starbuck, Michael
    Broom, Bradley
    Iyer, Matthew
    Logothetis, Christopher
    Chinnaiyan, Arul
    Navone, Nora
    CANCER RESEARCH, 2018, 78 (16) : 37 - 38
  • [50] Dissecting and targeting the activation pathway of BAX to reactivate apoptosis in cancer
    Gavathiotis, Evripidis
    Ruiz, Denis R.
    Davis, Marguerite L.
    Bird, Gregory H.
    Walensky, Loren D.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S45 - S45
12345